Clinical Characteristics, Treatment and Evolution of Splenic and Nodal Marginal Zone Lymphomas-Retrospective and Multicentric Analysis of Portuguese Centers
| Autor: | Catarina Dantas Rodrigues, Fernando Príncipe, Catia L Gaspar, João Paulo Fernandes, Pedro Chorão, Lídia Alves Ribeiro, Daniela Alves, M Eduarda Couto, Rita Coutinho, Henrique Coelho, Margarida Badior, Pedro de Vasconcelos M, Rita Pinho Peixeiro, Diana Viegas, Maria Gomes da Silva, Sérgio Chacim, Ana Tome |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Splenectomy Aggressive lymphoma Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Statistical significance medicine Humans Cumulative incidence Prospective Studies Aged Retrospective Studies Aged 80 and over Portugal business.industry Incidence (epidemiology) Incidence Splenic Neoplasms Hematology Lymphoma B-Cell Marginal Zone Middle Aged medicine.disease Lymphoma Treatment Outcome Oncology 030220 oncology & carcinogenesis Rituximab Female business Splenic Lymphoma 030215 immunology medicine.drug |
| Zdroj: | Clinical lymphoma, myelomaleukemia. 21(11) |
| ISSN: | 2152-2669 |
| Popis: | Introduction Treatment of Splenic (SMZL) and Nodal (NMZL) Marginal Zone Lymphoma is not consensual. Histologic transformation (HT) to aggressive lymphoma is a poorly understood event, with an unfavorable outcome. Objectives Describe the clinical characteristics, treatment, outcomes and incidence of HT. Methods Characteristics of patients with SMZL and NMZL consecutively diagnosed in 8 Portuguese centers were retrospectively reviewed. Endpoints were overall survival (OS), time to first systemic treatment (TTFST), frequency of HT and time to transformation (TTT). Results This study included 122 SMZL and 68 NMZL, most of them received systemic treatment: 55.4% and 76.5%, respectively. Splenectomy was performed in 58.7% of patients with SMZL. Different treatment protocols were used. OS or TTFST did not differ significantly according to treatments. Given the small sample size, no conclusion can be made concerning the role of Rituximab in the treatment of NMZL and SMZL based in these results. HT was documented in 18 patients, mainly in SMZL, with a cumulative incidence at 5 years of 4.2%. We confirmed that age is a prognostic factor. Conclusion Randomized prospective trials are needed to standardize treatment in MZL. Patients with HT did appear to have shorter OS in comparison with those who did not experience HT (OS 5 years of 68.4% vs. 80.4%), but the number of HT was too small to reach statistical significance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect